Open an account

Collegium Pharmaceutical

COLL · NASDAQ

$23.23+$0.22 (+0.96%)TodayMarket closed ·
Prev close $23.01

About COLL

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 423 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.

Employees
423
Headquarters
Stoughton, Massachusetts
Listed
May 7, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
collegiumpharma.com

COLL key statistics

Market cap
756.27M
Price-earnings ratio
18.71
Dividend yield
—
Average volume
761.55K
Volume
536.18K
Open price
$23.54
High today
$23.84
Low today
$22.90
52 Week high
$50.79
52 Week low
$21.43

Collegium Pharmaceutical (COLL) at a glance

As of Oct 20, 2026, Collegium Pharmaceutical (COLL) shares are priced at $23.23, giving the company a market cap of 756.27M and a price-to-earnings ratio of 18.71.

Today the stock has traded between $22.90 and $23.84. The current price is 1.5% above the day's low and 2.6% below its high.

Volume so far is 536.18K shares, below the average of 761.55K shares a day.

Over the past year Collegium Pharmaceutical has ranged from $21.43 to $50.79, and now sits 6% of the way up that range.

Collegium Pharmaceutical met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $1.92 per share against an estimate of $1.75.

The average analyst price target is $49.98, 115.2% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

86%of 7 analyst ratings say Buy
  • Buy85.7%
  • Hold14.3%
  • Sell0.0%
Price target · 10 analystsAvg $49.98
Low
$43.43
Now
$23.23
High
$63.00

COLL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 7.1% on average.

  1. Q3 FY24: reported $1.61 per share against an estimate of $1.62
  2. Q4 FY24: reported $1.77 per share against an estimate of $1.57
  3. Q1 FY25: reported $1.49 per share against an estimate of $1.46
  4. Q2 FY25: reported $1.68 per share against an estimate of $1.65
  5. Q3 FY25: reported $2.25 per share against an estimate of $2.08
  6. Q4 FY25: reported $2.04 per share against an estimate of $2.37
  7. Q1 FY26: reported $1.76 per share against an estimate of $1.62
  8. Q2 FY26: reported $1.92 per share against an estimate of $1.75

COLL news

  • Press releaseGlobe Newswire

    Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

  • Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings)

  • What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical

  • Earnings Scheduled For November 6, 2025

  • Press releaseGlobe Newswire

    Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

  • Earnings Scheduled For May 8, 2025

  • What Analysts Are Saying About Collegium Pharmaceutical Stock

  • Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical

Similar companies

Companies in the same industry as Collegium Pharmaceutical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.